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Soluble apoE/Aβ complex: mechanism and
therapeutic target for APOE4-induced AD risk
Leon M Tai1, Shipra Mehra1, Varsha Shete1, Steve Estus2, G William Rebeck3, Guojun Bu4 and Mary Jo LaDu1*
Abstract
The APOE4 allele of apolipoprotein E (apoE) is the greatest genetic risk factor for Alzheimer’s disease (AD) compared
to APOE2 and APOE3. Amyloid-β (Aβ), particularly in a soluble oligomeric form (oAβ), is considered a proximal cause
of neurodegeneration in AD. Emerging data indicate that levels of soluble oAβ are increased with APOE4, providing
a potential mechanism of APOE4-induced AD risk. However, the pathway(s) by which apoE4 may increase oAβ levels
are unclear and the subject of continued inquiry. In this editorial review, we present the hypothesis that apoE
isoform-specific interactions with Aβ, namely apoE/Aβ complex, modulate Aβ levels. Specifically, we propose that
compared to apoE3, apoE4-containing lipoproteins are less lipidated, leading to less stable apoE4/Aβ complexes,
resulting in reduced apoE4/Aβ levels and increased accumulation, particularly of oAβ. Evidence that support or
counter this argument, as well as the therapeutic significance of this pathway to neurodegeneration, are discussed.
Keywords: Alzheimer’s disease, Amyloid beta, Apolipoprotein E, Apolipoprotein E/amyloid beta complex,
Oligomeric amyloid beta, Lipoprotein, Lipidation
Introduction
Sporadic Alzheimer’s disease (AD) accounts for more
than 95% of all AD cases and the APOE4 allele of apoli-
poprotein E (apoE) is the greatest genetic risk factor;
two copies of the APOE4 allele increase AD risk up to
15-fold relative to APOE3. APOE4 carriers account for
more than half of AD patients and APOE4 accelerates
onset of cognitive impairment by 7-9 years per allele
[1,2]. The proposed mechanism(s) through which APOE4
increases AD risk are multifactorial, including both
amyloid-β (Aβ)-dependent effects, i.e. modulation of Aβ
levels, aggregation, neurotoxicity and neuroinflammation,
and Aβ-independent effects, i.e. neuronal development,
glucose metabolism, brain activity and lipid metabolism
(reviewed in [3]). In this editorial review, we propose the
hypothesis that apoE isoform-specific formation of soluble
apoE/Aβ complex modulates levels of neurotoxic Aβ,
providing a basis for APOE4-induced AD risk. Thera-
peutic implications are presented, as well as arguments
counter to this hypothesis.
N.B.: For the purpose of this paper, Aβ species will be
identified with as much detail as allowed by the detection
method of a specific publication i.e. “soluble Aβ42” if
measured in a soluble extraction fraction or soluble sample
with an Aβ42-specific ELISA or “soluble oAβ” if measured
in a similar sample using an oligomer-specific detection
method (for example, [4]). More general classes of Aβ
species will be referred to simply as Aβ or soluble Aβ.
Does APOE modulate soluble Aβ levels?
Genetic and experimental evidence posits soluble Aβ as
the proximal neurotoxin in AD. However, as a number
of potentially neurotoxic forms of the Aβ peptide exist,
the identity of the exact neurotoxic form of the peptide,
if there is indeed only one, is unclear. The different forms
of soluble Aβ have ambiguous and often overlapping defi-
nitions based on the method of detection (e.g. biochemical
or immunohistochemical analysis) and include; soluble
Aβ [5-7], oligomeric Aβ (oAβ [8-11]) and Aβ present in
amyloid plaques [12-16]. Further complications include;
1) a dynamic compartmentalization between the different
types of Aβ in the CNS i.e. between plaques and soluble
Aβ [17,18]; and 2) different forms of Aβ contributing to
neurodegeneration at different stages of the disease [19].
While plaque burden may not specifically correlate with
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cognitive dysfunction in AD, an emerging consensus is
that soluble Aβ42 and oAβ represent major proximal,
neurotoxic species in AD [15,20]. Indeed, soluble Aβ and
oAβ correlate with cognitive decline and disease severity
in humans [21], and oAβ levels are associated with
memory decline in transgenic mice expressing familial-
AD (FAD) mutations (FAD-Tg) (for review [21]).
In both FAD-Tg mice and humans, APOE4 is associated
with higher levels of insoluble Aβ, the result of an increase
in total plaque burden and extracellular Aβ compared to
APOE2 and APOE3 [22-25]. Importantly, in FAD-Tg mice
crossed with apoE-targeted replacement mice (apoE-TR),
there are higher levels of both soluble Aβ42 [12,23] and
soluble oAβ (EFAD mice) [12], with APOE4 compared to
APOE3. In addition, using a gene transfer approach, viral
expression of APOE4 increases, and APOE2 decreases, ISF
Aβ42 levels in FAD-Tg mice [18]. The increased soluble
Aβ levels in FAD-Tg mice expressing APOE4 have been
confirmed in humans [4,26,27]. In AD patients with
APOE4 compared to APOE3, oAβ levels are higher
surrounding amyloid plaques [26], in isolated synapto-
neurosomes [26], synaptosome enriched extracts [28],
and in TBS brain extracts [27]. Furthermore, in human
CSF, oAβ levels are increased in AD patients compared to
non-AD (NAD) and are greater in APOE4/4AD patients
compared to APOE3/3AD patients [4].
Interpretation
As soluble Aβ is considered a major neurotoxin in AD,
the apparent correlation between APOE4 and increased
levels of particularly soluble oAβ suggests that understand-
ing the underlying pathway(s) that mediates this effect
may be critical to understanding the APOE4-induced
risk for AD. In turn, this fundamental biology could
inform rational drug design and development of successful
AD therapeutics.
Does APOE modulate soluble apoE/Aβ levels
and stability?
Historical perspective
ApoE isoform-specific effects on apoE/Aβ complex levels
may mediate the increased soluble Aβ and oAβ levels that
correlate with APOE4. Research efforts to determine the
effect of apoE isoform on in-vitro complex formation
(Table 1) or in-vivo apoE/Aβ complex levels (Table 2) have
been ongoing for the last ~20 years (see Table 1). These
studies demonstrate that the method of detection and the
source of the components for apoE/Aβ complex are crit-
ical parameters for experimental outcomes.
Method of detection
ApoE/Aβ complex is defined by the method of detection,
particularly the stringency of the assay conditions and the
method used to isolate the in-vivo complex. Methods
utilized to measure apoE/Aβ complex, in order of de-
creasing stringency, include: gel-shift assay of SDS-PAGE
(under reducing or non-reducing conditions), with Western
blot analysis (WB) [33,42,59,66,67]; density gradient
ultracentrifugation [68]; non-denaturing gradient gel
electrophoresis [59]; co-immunoprecipitation (IP) [46]; size
exclusion chromatography (SEC)/gel-filtration; and solid-
phase binding assays [29,38,45,47,51,69]. Using primarily
SDS-PAGE or SEC-isolation followed by dot blot (DB) or
WB (Table 1), apoE/Aβ complex is detected when exogen-
ous Aβ is combined with apoE-containing lipoproteins
from human plasma, CSF and cell culture supernatants.
However, methods with relatively high stringency can result
in disruption of the apoE/Aβ complex, thus confounding
interpretation of the data. The influence of assay stringency
is highlighted by the effect of detergent during SDS-
PAGE with WB analysis; in-vitro SDS-stable apoE3/Aβ
levels are greater than apoE4/Aβ [33], but comparable
when analyzed by non-denaturing gel electrophoresis
[59]. These data are consistent with an SDS-stable
apoE3/Aβ complex, and an apoE4/Aβ complex that is
disrupted by SDS (for review [56]). As well, the inclu-
sion of a reducing agent during SDS-PAGE (β-mercap-
toethanol, β-ME; dithiothreitol, DTT) disrupts both the
SDS-stable apoE3/Aβ and apoE4/Aβ complexes
[30,31,66].
For in-vivo apoE/Aβ complex (Table 2), assay stringency
also affects the levels of apoE/Aβ complex. In-vivo apoE/Aβ
complex has been detected in the soluble fraction of human
brain [46] and cerebrospinal fluid (CSF) [53,63] by SEC iso-
lation followed by DB or WB. The potential for in-vivo
apoE/Aβ complex to be disrupted by the method of de-
tection was demonstrated in one of the earliest apoE/
Aβ complex studies by Russo and co-workers [46].
When analyzed by co-IP, soluble brain apoE/Aβ com-
plex levels were lower in AD compared to non-AD
(NAD) patients. Importantly, complex from AD patients
was less stable to SDS-PAGE with WB analysis and more
susceptible to enzymatic degradation [46].
Source of apoE/Aβ complex
ApoE is the major apolipoprotein present on CNS lipo-
proteins (for review [70]). In the CNS, apoE is produced
primarily by glia (astrocytes and microglia), although
under certain conditions neuronal apoE expression may
occur [71]. Because apoE is an apolipoprotein, interactions
with Aβ depend on the lipidation state of the apoE-
containing lipoproteins (see below) i.e. whether the apoE is
purified [33,42,51,66], lipid-poor [33,51,54], reconstituted
with lipids from HDL [51], astrocyte-secreted [59],
CSF-derived [29], or isolated plasma-lipoproteins [42,66,68].
Thus, evaluating the in-vitro interactions between apoE and
Aβ influenced by the source of apoE. For example,
purified apoE4 binds Aβ with a higher affinity than
Tai et al. Molecular Neurodegeneration 2014, 9:2 Page 2 of 14
http://www.molecularneurodegeneration.com/content/9/1/2
Table 1 Effect of apoE isoform on soluble in-vitro apoE/Aβ complex levels
Study Human apoE source Aβ source apoE:AβMolar Ratio Detection Method Results
Strittmatter et al,
1993 [29,30]
Human CSF
(NAD & AD)
Syn. Aβ40,
1-28, 12-28
*
(100μl CSF:2.5mM)
SDS-PAGE
(Reducing), WB
apoE binds to Aβ40, 1-28, 12-28
Human plasma (Purified) Syn. Aβ40 1:170 SDS-PAGE
(Non-reducing), WB
apoE4/Aβ > apoE3/Aβ
Stability at 4.6 pH = apoE3/Aβ > apoE4/Aβ
(<10% apoE binds Aβ)
Wisniewski et al,
1993 [31]
Human CSF
(NAD & AD)
Syn. Aβ40,
Aβ42
*
(50μg CSF:2μg/ml)
SDS-PAGE
(Reducing), WB
apoE/Aβ at 34kDa
Sanan et al
1994 [32]
Human plasma (Purified) Syn. Aβ28 1:139 SDS-PAGE
(Non-reducing), WB
apoE3/Aβ > apoE4/Aβ
LaDu et al,
1994 [33]
HEK293 (CM) apoE3/Aβ > apoE4/Aβ
LaDu et al,
1995 [34]
HEK293 (Purified & CM),
Human plasma
(Native & purified)
Syn. Aβ40 1:357 SDS-PAGE
(Non-reducing), WB
CM & plasma (native):
apoE3/Aβ40 > apoE4/Aβ40
Purified apoE (both sources):
apoE3/Aβ40 = apoE4/Aβ40
Castano et al,
1995 [35]
Recombinant # Syn. Aβ40 1:169 SDS-PAGE
(Non-reducing), WB
apoE3/Aβ40 at 40kDa
Naslund et al,
1995 [36]
Recombinant #
Syn. Aβ40,
Aβ42 1:136
SDS-PAGE
(Non-reducing &
reducing), WB
Non-reducing: apoE3/Aβ = apoE4/Aβ
Reducing: higher molecular mass
complexes
Golabek et al,
1995 [37]
Recombinant # Syn. Aβ40 1:8.5 SDS-PAGE
(Non-reducing), WB
apoE/Aβ at >36kDa
Golabek et al,
1996 [38]
Recombinant # Syn. Aβ40 *(0-150nM:2.5pmol) Solid plate assay apoE2/Aβ = apoE3/Aβ = apoE4/Aβ
Shuvaev & Siest et al,
1996 [39]
Human plasma (Purified) Syn. Aβ40 1:130 Surface plasmon
resonance
apoE3/Aβ > apoE4/Aβ = apoE2/Aβ
(↑ apoE3/Aβ with ↑ salt concentration &
unaffected in pH 6-8)
Chan et al,
1996 [40]
Ecoli (Purified),
Human plasma (Purified)
Syn. Aβ40 1:3-1:11 SDS-PAGE
(Non-reducing), WB, Gel filtration
apoE4/Aβ = apoE3/Aβ = apoE2/Aβ
(Both sources gave same results, Aβ &
apoE tetramer co-migrate)
Zhou et al,
1996 [41]
RAW264 (CM) Syn. Aβ40 1:170 SDS-PAGE
(Non-reducing), WB
apoE3/Aβ >> apoE4/Aβ (ND)
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Table 1 Effect of apoE isoform on soluble in-vitro apoE/Aβ complex levels (Continued)
LaDu et al,
1997 [42]
HEK293 (CM),
Human plasma
(Native & Purified), rat &
rabbit apoE (native)
Syn. Aβ40
1:357 (CM),
1:715
(Plasma)
SDS-PAGE
(Non-reducing), WB
Native: apoE2/Aβ = apoE3/Aβ = rabbit
apoE/Aβ > apoE4/Aβ (ND) = rat apoE/Aβ
Purified: apoE2/Aβ = apoE3/Aβ >
apoE4/Aβ (ND)
(Both CM & human plasma - native gave same results)
Yang et al,
1997 [43]
CHO (CM),
Human plasma
Syn. Aβ40
1:97 (CM),
1:850
(Plasma)
SDS-PAGE
(Non-reducing), WB
apoE3/Aβ = apoE2/Aβ >> apoE4/Aβ (ND)
(Both sources gave same results)
Aleshkov et al,
1997 [44]
BHK21 (CM),
Recombinant #
(Lipidated),
Human plasma
Syn. Aβ40 1:126 SDS-PAGE
(Non-reducing), WB
Recombinant & CM (apoE monomer):
apoE2/Aβ > apoE3/Aβ >> apoE4/Aβ
Plasma: apoE3/Aβ > apoE4/Aβ
Pillot et al,
1997 [45]
Recombinant #
Syn. Aβ29-
40/42
1:5-1:100
SDS-PAGE
(Non-reducing), WB
apoE2/Aβ = apoE3/Aβ > apoE4/Aβ (ND)
(Dose dependent ↑ complex with ↑ ratio Aβ:apoE3 or apoE2)
Russo et al,
1998 [46]
Human plasma apoE #
Syn. Aβ42,
Human Aβ
(Brain)
*
(17.7pmol:100μM) IP with SDS-PAGE WB apoE/Aβ complex at 40kDa
Pillot et al,
1999 [47]
Recombinant # Syn. Aβ29-40, Aβ29-42 1:50 SDS-PAGE
(Non-reducing), WB
CTF-apoE/Aβ > NTF-apoE/Aβ (ND)
Yamauchi et al,
1999 [48]
Recombinant #
(Non-lipidated & lipidated)
Syn. Aβ42 1:2-1250 ELISA apoE2/Aβ > apoE3/Aβ > apoE4/Aβ(No differences in lipidated vs. non-lipidated in apoE isoform)
Aleshkov et al,
1999 [49]
BHK1 (CM) Syn. Aβ40 1:125 SDS-PAGE
(Non-reducing), WB
apoE2/Aβ = apoE2-Thr194-Ala/Aβ =
apoE4-Arg158-cys/Aβ
Golabek et al,
2000 [50]
Syn. Aβ40 1:8.5 SDS-PAGE
(Non-reducing), WB
Recombinant #
Human plasma
(Purified)
Recombinant:
NTF-apoE3/Aβ > CTF-apoE3/Aβ
Plasma: apoE/Aβ at 38kDa
Tokuda et al,
2000 [51]
RAW264 & HEK293
(CM, delipidated),
Sf9 insect cells
(Delipidated & lipidated)
Syn. Aβ40,
Aβ42
*
(0-150nM/2.5pmol) ELISA
CM & Sf9 (Lipidated): apoE3/Aβ >
apoE4/Aβ
All sources (Delipidated): apoE3/Aβ =
apoE4/Aβ
(apoE/Aβ: CM > Sf9 lipidated)
Drouet et al,
2001 [52]
Ecoli (Purified) Syn. Aβ29-40 1:100 SDS-PAGE
(Non-reducing), WB
apoE/Aβ-CTF: apoE2/Aβ = apoE3/Aβ >
apoE4/Aβ (ND)
Zhou et al,
2002 [53]
RAW264 (CM),
CSF (NAD E3/3, PAD E3/4,
AD E4/4)
Syn. Aβ40
1:250 (CM),
* (CSF)
(70μl CSF:100μM)
co-IP, SDS-PAGE
(Non-reducing), WB
CM: apoE3/Aβ >> apoE4/Aβ
CSF: APOE33/Aβ > APOE34/Aβ =
APOE44/Aβ (ND)
(With BMEless apoE3/Aβ)
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Table 1 Effect of apoE isoform on soluble in-vitro apoE/Aβ complex levels (Continued)
Bentley et al,
2002 [54]
HEK293 (CM) Syn. Aβ40 1:340 SDS-PAGE
(Non-reducing), WB
apoE3/Aβ > apoE4/Aβ =
apoE3-Ala-112/Aβ = apoE4-Lys-112/Aβ
(ApoE3-Thr-61/Aβ = apoE4-Thr-61/Aβ = no complex)
Gylys KH et al,
2003 [55]
Recombinant #
(Lipidated)
Syn. Aβ40 1:5.6 SDS-PAGE
(Non-reducing), WB
apoE3/sAβ > apoE3/agg Aβ
Manelli et al,
2004 [56]
HEK293 (CM) Syn. Aβ42 1:33 SDS-PAGE
(Non–reducing), WB
apoE3/oAβ > apoE3/Aβ fibrils >
apoE4/oAβ > apoE4/Aβ fibrils
Phu et al,
2005 [57]
Recombinant #
Syn.
AEDANS-
F4C- Aβ42
1:1 FRET Soluble complex: CTF-apoE/Aβ
Stratman et al,
2005 [58]
Recombinant #
(Lipidated)
Syn. Aβ40 1:500 ELISA Intermediate agg Aβ40:
apoE4/Aβ >> apoE2/Aβ = apoE3/Aβ
Morikawa et al,
2005 [59]
Immortalized astrocytes
apoE-TR (CM immuno-purified),
Primary astrocytes GFAP-apoE-Tg
(CM Immuno-purified)
Syn. Aβ40 1:4.5-22.5
SDS-PAGE
(Reducing &
non-reducing),
WB
(Physiological buffer in
non - reducing)
Reducing: apoE3/Aβ > apoE4/Aβ
Non-reducing: apoE3/Aβ = apoE4/Aβ
Wellnitz et al,
2005 [60]
N2a (CM) Syn. Aβ42 1:0.1-1000 SDS-PAGE
(Reducing), WB
CTF-apoE/hexameric Aβ:
apoE4/Aβ > apoE3/Aβ = apoE2/Aβ
Petrlova et al,
2011 [61]
Ecoli (Purified & lipidated) Syn. Aβ40 1:3.3 EPR spectroscopy
Purified apoE: apoE3/oAβ > apoE4/oAβ
Lipidated apoE: apoE3/Aβ > apoE4/Aβ
(CTF apoE bind Aβ)
Cerf et al,
2011 [62]
Ecoli (Purified) Syn. Aβ42 1:25-100 SDS-PAGE
(Non-reducing), WB
apoE monomers/agg Aβ: apoE3/Aβ =
apoE4/Aβ
(Stabilize oAβ42: apoE4 > apoE3)
Hashimoto et al,
2012 [27]
Immortalized astrocytes
apoE-TR (CM immuno-purified)
Syn. Aβ42 1:0.083 SDS-PAGE
(Reducing), WB
No complex measured
Lipidated apoE stabilizes oAβ42: apoE4 >
apoE3 > apoE2
LaDu et al,
2012 [63]
Human Plasma (NAD),
Rat Astrocyte
(CM, isolated, purified delipidated)
Syn. Aβ40 SEC, SDS-PAGE
(Non–reducing), WB
1:5-16 (Plasma);
1:36
(Rat ACM); 1:357
(Rat isolated & purified)
Aβ co-elutes with apoE containing
lipoproteins: Human plasma (70%) >
rat ACM (53%)
Monomer apoE/Aβ (45kDa) & dimer
apoE/Aβ 97kDa : rat isolated > rat purified
Ly et al,
2013 [64]
Ecoli (Purified) Syn. Aβ40 1-4:1, 1:2 Laser fluorescence
spectroscopy
Stable complex- apoE3L-Cys-264/oAβ >
apoE4-Cys-264/oAβ
(apoE3L means “apoE3 like” with Cys112-Ser)
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Table 1 Effect of apoE isoform on soluble in-vitro apoE/Aβ complex levels (Continued)
Tai et al,
2013 [4]
HEK293 (CM) Syn. Aβ42 1:0.005-50 ELISA
Total complex: apoE2/Aβ = apoE3/Aβ =
apoE4/Aβ
SDS stable: apoE2/Aβ > apoE3/Aβ >
apoE4/Aβ
pH=5: apoE2/Aβ = apoE3/Aβ > apoE4/Aβ
Verghese et al,
2013 [65]
Recombinant #
(Lipidated)
APP H4
neuroglioma
(CM), Syn. Aβ40/42
1:0.02-0.05 (CM),
1:0.2-1 (Syn.)
Density gradient
ultracentrifugation,
SEC, ELISA, FCS (Reducing)
Monomeric Aβ free (95-97%) >>
apoE3/Aβ = apoE4/Aβ
(Lipidated apoE poorly binds binds Aβ)
Immortalized astrocytes
apoE-TR
(CM immuno-purified),
Primary astrocytes
GFAP-apoE-Tg
(CM Immuno-purified)
APP H4
neuroglioma (CM),
7PA2 cells (CM)
1:0.04 (H4), 1:0.05
(7PA2)
SEC, ELISA, FCS (Reducing)
Higher order Aβ species (free) >>
apoE3/Aβ = apoE4/Aβ
Human CSF (Pooled
non-concentrated, NAD)
APP H4
neuroglioma
(CM)
*
(800μl CSF:50ng/ml) SEC
95% in vitro Aβ (free) =
in vivo Aβ (free) >> apoE/Aβ
#, Commercially purchased recombinant human apoE; *, apoE:Aβ ratio unknown; Lipidated apoE is either with POPC, reconstituted “HDL” or plasma lipoprotein.
ACM, Astrocyte conditioned media; AD, Alzheimer’s disease; agg Aβ, Aggregated Aβ; BME, β - mercaptoethanol; CSF, Cerebrospinal fluid; CM, Conditioned media; co-IP, co - immunoprecipitation; CTF, C-terminal
fragment; EPR, Electron paramagnetic resonance; ELISA, Enzyme-linked immunosorbent assay; FCS, Fluorescence correlation spectroscopy; FRET, Fluorescence resonance energy transfer; IP, Immunoprecipitation; NAD,
Non-AD or non-dementia control; ND, Not detectable; NTF, N-terminal fragment; oAβ, Oligomeric Aβ; PAD, Probable AD; PAGE, Polyacrylamide gel electrophoresis; sAβ, Soluble Aβ; Sf9, Spodoptera frugiperda insect
cells; SDS, Sodium dodecyl sulfate; SEC, Size exclusion chromatography; Syn, Synthetic; Tg, Transgenic; TR, Target replacement; WB, western blot.
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Table 2 Effect of apoE isoform on soluble in-vivo apoE/Aβ complex levels
Study Biological source Detection method Results
Naslund et al, 1995 [36] Human brain (AD & NAD) SDS-PAGE AD > NAD, No apoE isoform differences measured
Russo et al, 1998 [46] Human brain (AD & NAD) IP, SDS-PAGE WB NAD apoE23/Aβ = NAD apoE33/Aβ = NAD apoE34/Aβ >>
AD apoE33/Aβ > AD apoE44/Aβ
SDS & protease digestion stability: NAD > AD
Yamauchi et al, 1999 [48] Human CSF & serum (NAD) SDS-PAGE (Non-reducing), WB apoE33/Aβ > apoE44/Aβ (ND)
Hashimoto et al, 2012 [27] Human brain (NAD) SEC, SDS-PAGE (Reducing), WB No complex measured, HMW Aβ interacts with apoE on HDL particles
LaDu et al, 2012 [63] Human plasma (NAD) SEC, SDS-PAGE (Non-reducing), WB 95% Aβ elutes with lipoproteins
Human CSF (NAD) 100% Aβ associated with apoE containing lipoproteins, apoE
monomer/Aβ (45 kDa) & apoE dimer/Aβ (97 kDa) detected
Tai et al, 2013 [4] Hippocampal homogenates (EFAD mice) ELISA SDS stable: E2FAD > E3FAD > E4FAD Total complex: E2FAD = E3FAD > E4FAD
Human cortical synaptosomes (AD & NAD) Total complex:
• NAD > AD
• NAD apoE33/Aβ = NAD apoE4X/Aβ > > AD apoE33/Aβ > AD apoE4X/Aβ
SDS stable:
• NAD apoE33/Aβ > > NAD apoE4X/Aβ
Human CSF (AD & NAD) NAD > AD, NAD apoE33/Aβ > AD apoE33/Aβ > AD apoE44/Aβ
Verghese, et al, 2013 [65] Human CSF (NAD) SEC, ELISA 95% Aβ (free) > > apoE33/Aβ = apoE44/Aβ
No apoE isoform differences
(In co-elution peak stoichiometric ratio of apoE:Aβ = 1:0.0002-0.0003)
AD, Alzheimer’s disease patients; CSF, Cerebrospinal fluid; ELISA, Enzyme-linked immunosorbent assay; HDL, High density lipoprotein; HMW, High molecular weight; IP, Immuno-precipitation; NAD, Non-AD or
non-dementia control; ND, Not detected; PAGE, Polyacrylamide gel electrophoresis; SDS, Sodium dodecyl sulfate; SEC, Size exclusion chromatography; WB, Western blot.
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apoE3 [30,66]. However, this affinity is reversed using
lipidated apoE; levels of apoE3/Aβ complex are significantly
greater than apoE4/Aβ complex [30,33,66].
Interpretation
Landmark studies are consistent with the decreased
stability of in-vitro apoE4/Aβ complex compared to the
apoE3/Aβ when a “physiological relevant” source of
apoE is used. Further, the presence of both detergent
and a reducing agent significantly reduce complex levels,
with apoE4/Aβ affected more than apoE3/Aβ. Import-
antly, soluble levels of in-vivo apoE/Aβ complex levels are
lower and the complex less stable in AD versus NAD
brain samples, suggesting a link between apoE isoform-
specific formation of apoE/Aβ complex and AD, for
which APOE4 is the greatest risk factor.
Recent data
Is there a soluble apoE/Aβ complex?
A recent publication by Verghese and co-workers brought
into question the significance of the apoE/Aβ complex for
modulating Aβ levels [65]. Although the overall goal of
the study was to determine the effect of apoE/Aβ complex
on Aβ metabolism, the authors noted that apoE forms
minimal complex with Aβ [65]. For in-vitro apoE/Aβ
complex, only 5% of cell-derived Aβ formed a complex
with apoE (astrocyte derived or lipid reconstituted) when
analyzed using gradient ultracentrifugation, SEC followed
by ELISA analysis and fluorescence correlation spectros-
copy (FCS) [65]. The apparent difference between these
results and previous studies, where cell-derived apoE and
Aβ formed a significant amount of apoE/Aβ complex, was
attributed to a non-physiologically high ratio of Aβ to
apoE. Indeed, previous studies often added Aβ in excess of
apoE (Table 1), whereas Verghese and co-workers used
“physiological” ratios of apoE to Aβ [65]. However, in CSF,
plasma and brain homogenates from humans and FAD-
Tg mice, the concentrations of Aβ are significantly
lower than apoE. For example, the apoE:Aβ ratios re-
ported for human CSF are in the range of 1:0.006-0.02
[72-74]. In addition, density gradient centrifugation is
known to induce loss of (apolipo)proteins from lipopro-
teins [67], which would likely effect the components of
the apoE/Aβ complex isolated by this method. Finally,
FCS analysis requires β-ME, which disrupts apoE/Aβ
complex [42].
Verghese and co-workers report similar results for in-
vivo apoE/Aβ complex in human CSF, with only ~5% of
apoE and Aβ co-eluting from SEC in fractions analyzed by
ELISA [65]. This is in contrast to a previous study that
demonstrated ~100% co-elution of apoE and Aβ from
human CSF [63]. Although no data are presented, the
hypothesis is that concentration of the CSF 10-30-fold
prior to SEC as used in the previous publications [63,75],
may have induced apoE/Aβ complex formation.
APOE modulates soluble apoE/Aβ levels measured by ELISA
To determine the effect of apoE isoform on apoE/Aβ
complex levels under non-stringent conditions, we de-
veloped an apoE/Aβ complex ELISA to detect both the
total levels of apoE/Aβ complex and, after the addition
of SDS, the stability of the apoE/Aβ complex [4]. With
this technique, using cell-derived apoE and synthetic
Aβ42 at physiological ratios (in-vitro complex), total
apoE/Aβ complex levels were equivalent for the three
apoE isoforms, whereas SDS-stability of the apoE/Aβ
complex was isoform-specific; apoE2/Aβ > apoE3/Aβ >
apoE4/Aβ, consistent with previous results utilizing alter-
native, non-stringent detection methods [33,41,42,54].
In addition, using this ELISA, the apoE/Aβ complex
is less stable at a low pH [4], also in agreement with
previous data [66].
With the apoE/Aβ complex ELISA, we also identified
an APOE genotype-specific difference in in-vivo apoE/
Aβ complex levels in EFAD-Tg mice and human samples
[4]. In EFAD-Tg mice, soluble levels of apoE4/Aβ com-
plex were lower and less stable compared to apoE3/Aβ
and apoE2/Aβ. Further, soluble oAβ levels were higher
in E4FAD mice compared to E2FAD and E3FAD mice,
suggesting that apoE/Aβ complex may modulate oAβ
levels. In human synaptosome preparations and CSF,
apoE/Aβ levels were lower in AD compared to NAD sam-
ples, and with APOE4 compared to APOE3 in the AD co-
hort. Importantly, in human CSF, oAβ increased and was
greater with APOE4 in the AD cohort, in contrast to total
Aβ42 levels that decrease with AD compared to NAD,
with levels at the limit of detection in the AD cohort
with both APOE3 and APOE4. Taken together, the low
levels of soluble apoE4/Aβ complex and high levels of
soluble oAβ suggest a potential basis for APOE4-in-
duced AD risk.
Interpretation
As we seek to define the role of apoE/Aβ complex in the
parenchyma of the brain, extracting intact lipoproteins
from tissue homogenates is critically important but
procedurally problematic. For now, the optimal CNS
samples are soluble brain homogenates or CSF. In
addition, as discussed in the previous section, multiple
factors are known to influence the detection of apoE/
Aβ complex levels. One technique is not necessarily
superior to another; each has merits and limitations.
Thus, future studies may utilize multiple, complementary
techniques for sample analysis. Overall, based on the
literature and our recent data demonstrating an inverse
relationship between the levels of soluble apoE/Aβ
complex and oAβ, we hypothesize that complex plays a
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significant role in modulating oAβ levels. The lower
levels and instability of apoE4/Aβ complex compared
to apoE3/Aβ suggests a potential mechanism for the
APOE4-induced risk for AD.
Does apoE isoform-specific lipoprotein lipidation
affect apoE/Aβ complex levels?
CNS apolipoproteins are exclusively produced within the
brain and apoE is the major apolipoprotein in the CNS
[70]. The biogenesis of CNS apolipoproteins occurs
primarily in the interstitial fluid and a proposed model
of lipoprotein remodeling includes: 1) glial cells secrete
nascent apoE-containing lipoproteins that are lipid-poor
and discoidal in shape; 2) ABCA1 and ABCG1 in glia
and neurons efflux free cholesterol to these lipoproteins,
increasing the lipidation state of this now intermediate
lipoprotein particle; and 3) intermediate particles mature
and likely become spherical through acquiring a choles-
teryl ester core and additional phospholipids [76]. Thus,
apoE isoform-specific lipoprotein lipidation is a critical
parameter that modulates the overall function of these
lipoproteins, including the formation of apoE/Aβ complex.
ApoE modulation of lipoprotein lipidation
The general dogma in the field is that apoE4 in the CNS
is less lipidated than apoE3. However, it is difficult to
isolate and analyze intact CNS lipoproteins, thus limiting
direct study of the lipidation state of apoE4-particles
versus apoE3-particles. However, the functional conse-
quences of conditions predicted to affect the lipidation
state of lipoproteins have provided valuable insights. For
example, in vitro data demonstrate that glia-mediated
degradation of apoE is increased and cholesterol release
is reduced in primary glial cultures expressing apoE4
compared to apoE3 [77,78]. In vivo study of Tg mice using
over-expression or knock-out of the ABC transporters has
also provided important information on the functional
effects of the lipidation state of CNS lipoproteins [79-82].
For example, Fitz and co-workers demonstrated that
introducing ABCA1-/+ to an FAD/apoE-Tg mouse results
in increased plaque deposition and a general AD pheno-
type in mice expressing apoE4 but not apoE3 [82]. In
addition, we recently developed a three-step sequential
protein extraction protocol (TBS, TBSX, formic acid/FA).
A non-ionic detergent Triton X-100 (TBSX) is used to
in an attempt to release apoE from lipoprotein particles
without inducing the formation of new micelles, as can
occur with ionic detergents such as SDS [12,83]. Using
EFAD mouse brain extraction fractions, we demonstrated
that while total brain apoE4 levels are lower compared to
apoE2 and apoE3, this decrease is seen only in the TBSX
fraction [12]. These data provide evidence that less apoE4
is associated with lipoproteins and thus apoE4 may be less
lipidated than apoE2 and apoE3.
ApoE lipoprotein lipidation and apoE/Aβ complex levels
Biophysical data demonstrates that, compared to apoE3,
apoE4 has an increased propensity to populate an
intermediate molten globule state during denaturation,
suggesting a less stable conformation [84-86]. Thus, the
decreased stability of apoE4-containing lipoproteins may,
in part, explain the decreased stability of the apoE4/Aβ
complex compared to the apoE3/Aβ complex. An add-
itional consideration is whether apoE and Aβ form a direct
complex, or whether Aβ interacts with the lipid surface of
apoE-containing lipoproteins, which likely comprise a
relatively larger surface area of the lipoprotein particle
compared to apoE. Simplistically, if apoE4-containing
lipoproteins are less lipidated than apoE3-containing
lipoproteins, then a smaller surface area is provided on
a less stable lipoprotein for interactions with Aβ.
Interpretation
Identifying whether apoE4-containing lipoproteins are less
lipidated than apoE3- containing lipoproteins, and which
lipids differ between the two, are important consider-
ations. If, as hypothesized, apoE4-containing lipoproteins
are less lipidated than apoE3 containing lipoproteins,
this may explain the reduced levels and stability of the
apoE4/Aβ complex.
How might apoE/Aβ complex modulate soluble
Aβ levels?
The functional key question in this field is how apoE/Aβ
complex modulates soluble Aβ levels. Although there are
a number of proposed mechanisms, they generally fall
into 2 categories: 1) modulation of Aβ clearance, and 2)
Aβ aggregation.
Aβ clearance
The Aβ clearance rate is slower with apoE4 compared to
apoE3 in PDAPP/apoE-TR mice [87] and in apoE-TR mice
after a bolus brain injection of Aβ [88]. ApoE exhibits an
isoform-specific effect on a number of cellular processes
that modulate soluble Aβ clearance, and the mechanisms
underlying these effects may be influenced by apoE/Aβ
complex levels. Compared to apoE3, apoE4 results in a
decrease in Aβ levels via: 1) clearance via glia [89-93],
neurons [94-96], and the blood-brain barrier [88,97]; 2)
intracellular and parenchymal enzymatic degradation
[93]; and 3) drainage via the interstitial fluid (ISF) [87]
and perivasculature [98]. One potential mechanism is
that soluble apoE3/Aβ complex may reduce soluble Aβ
levels via clearance, whereas the lower levels of soluble
apoE4/Aβ complex result in higher soluble Aβ levels,
particularly oAβ. In terms of cellular clearance, the lit-
erature appears contradictory, likely due to the variety
of models and reagents used, including; glia versus
neurons, mouse versus human cells, mouse versus
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human apoE, source of apoE (purified protein or lipidated
particle), source and aggregation state of the Aβ, etc. In
a particularly relevant study, Nielson and co-workers
used primary human astrocytes to address the role of
the human apoE isoforms in binding and uptake of
Aβ42. Their results demonstrated that both apoE3 and
apoE4 inhibited the uptake of oAβ42 but not fibrillar
forms of the peptide [99].
Aβ aggregation
Data are conflicting as to the effect of apoE/Aβ complex on
Aβ aggregation. Previous publications have demonstrated
that apoE promotes Aβ aggregation, resulting in retention
of the peptide; within glia [99], as intraneuronal Aβ [100],
or in the parenchyma as either diffuse Aβ deposits or
amyloid [12]. APOE4 is associated with an increase in
amyloid deposition, suggesting that apoE functions as a
“pathological chaperone”, an effect that might actually be
beneficial [101]. However, as demonstrated in vitro, apoE
isolated from human brain increases the oligomerization
of Aβ [27], an effect that is greater with apoE4 compared
to apoE3. This is consistent with the hypothesis that apoE
binds to oAβ and prevents further aggregation [64]. These
results would favor the view that lower levels of apoE/Aβ
complex are beneficial [102,103].
Interpretation
Delineating the effect of apoE/Aβ complex on Aβ clear-
ance and aggregation is complex due to the multiple
mechanisms involved in these processes. It is particularly
difficult to interpret in vitro data as the studies focus on
multiple, different intercellular and intracellular pathways.
At this point, research appears to support a role for apoE/
Aβ complex in both promoting Aβ clearance and Aβ
aggregation, both as insoluble amyloid and soluble oAβ.
How can the apoE/Aβ complex be targeted
therapeutically?
Therapeutics that target the apoE/Aβ complex can be
broadly divided in those that increase the ability of apoE-
containing lipoproteins to form an apoE/Aβ complex and
those that disrupt apoE/Aβ complex.
Therapies to increase apoE/Aβ complex
Nuclear receptor agonists
Increasing the lipidation of apoE-containing lipoproteins
may increase apoE/Aβ complex levels and decrease oAβ
levels. As described above, the transporters ABCA1 and
ABCG1 expressed by glia and neurons in the CNS are
considered the major transporters of lipid to the nascent
CNS apoE-containing lipoproteins [76]. Agonists for the
nuclear receptors PPARγ [104-106], LXR (reviewed in
[107]) and RXR [108-111] increase ABCA1 and ABCG1
expression and decrease soluble Aβ levels in FAD-Tg
mice. However, controversy exists over the activity and
mechanism of action of these agents, highlighted by
recent data with the RXR agonist bexarotene [112]. Initial
data demonstrated that bexarotene increased apoE levels
and decreased soluble Aβ within hours and significantly
reduced insoluble Aβ after three days [112]. These data
were purported to be consistent with an apoE-induced
increase clearance of both soluble and insoluble Aβ.
However, very recent findings indicate that bexarotene
treatment of FAD-Tg mice reduced soluble Aβ and
improved memory without changing amyloid or apoE
levels but with increased ABCA1 expression [108-111].
Therefore, a potential novel mechanism of action of
RXR agonists is an increase in ABCA1 expression,
which results in increased lipid content/lipidation of
apoE-containing lipoproteins, a process that may be
particularly beneficial to lipid-poor apoE4-containing
lipoproteins. This increased lipidation likely results in
an increase in apoE/Aβ complex levels and a decrease
in soluble Aβ42 levels, as discussed in Section 4 above.
Dietary strategies
A recent publication highlighted the effect of APOE and
diet on Aβ levels and apoE lipidation in patients with
MCI [113]. The overall conclusion was that with a high
saturated fat or glycemic diet, apoE was less lipidated
and it formed lower levels of apoE/Aβ complex, resulting
in reduced Aβ clearance and increased Aβ oligomerization
and toxicity [113]. Thus, dietary interventions may prove
effective for raising apoE/Aβ complex levels.
Therapies to block apoE/Aβ complex
Aβ12-28P
The potential for apoE to increase Aβ aggregation, and
even specifically oligomerization, led to the development
of the Aβ12-28P, an Aβ peptide purported to block the
formation of apoE/Aβ complex [102,103]. In vivo data
demonstrate that Aβ12-28P lowers insoluble Aβ both in
the brain [102,103] and vasculature [114] of FAD-Tg mice.
However, data on the effect of this peptide on apoE/Aβ
complex levels are limited. In addition, Aβ12-28P has not
been tested in the absence of apoE (apoE-KO mice), leav-
ing open the possibility that it may be interacting directly
with Aβ to reduce aggregation. Therefore, the mechanism
of action of Aβ12-28P in vivo is currently unclear.
Interpretation
A major hurdle to interpreting how therapeutic or dietary
interventions modulate apoE/Aβ complex, Aβ accumula-
tion, and ultimately AD, is their pleiotropic mechanisms
of action. For example, LRX/RXR/PPARγ agonists display
anti-inflammatory actions, which may or may not be
dependent on lipoprotein lipidation, and ABCA1 may
directly clear Aβ. However, data with nuclear receptor
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agonists suggests that increasing ABCA1/ABCG1 expres-
sion will increase lipoprotein lipidation, apoE/Aβ complex
levels and Aβ clearance, thus reducing soluble oAβ levels.
Conclusions
Our hypothesis is that the APOE4-induced risk of AD is
consistent with the following pathway to neurodegenera-
tion: Compared to apoE3, apoE4-containing lipoproteins
are less lipidated, which reduces stability, resulting in lower
levels the apoE4/Aβ complex. Reduced levels of apoE4/Aβ
complex result in increased Aβ accumulation, specifically
oAβ levels. Thus, increasing the lipidation of apoE-contain-
ing lipoproteins may reduce Aβ accumulation, an effect
particularly effective with the lipid-poor apoE4-lipoproteins.
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